Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemisinin resistance marker surveillance and treatment outcomes in uncomplicated falciparum malaria in children in South-West Nigeria
PACTR202108584742856Phase 4Recruiting
- Sponsor
- Amusan Abiodun
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dihydroartemisinin + piperaquine and artemether + lumefantrine in malaria and Falciparum malaria (PF) (3 arms), sponsored by Amusan Abiodun. Primary endpoint: Treatment success or failure. Started Jun 2021; status: recruiting.
02
Drugs
dihydroartemisinin + piperaquineartemether + lumefantrine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR202108584742856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108584742856.